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Abstract
The enzyme tartrate resistant acid phosphatase (TRAP) is expressed in alveolar macrophages 
in high quantities but its function is unclear and stable inhibitors are lacking We studied 
changes in TRAP expression and activity in patients with chronic obstructive pulmonary disease 
(COPD), (fatal) asthma and found higher TRAP activity and expression in patients with COPD 
or fatal asthma compared to controls. In mouse models, more TRAP activity was detected in 
the lungs of mice following cigarette smoke or house dust mite exposure. Stimuli related to 
asthma or COPD (Receptor activator of NF-kb ligand (RANKL), M-CSF, IL-4, ATP, Xanthine/
Xanthine Oxidase) were tested for their capacity to induce TRAP in macrophages in vitro 
and in lung slices. RANKL and Xanthine/Xanthine Oxidase induced TRAP mRNA expression 
in mouse macrophages, but only RANKL induced TRAP activity in mouse lung slices. Several 
gold(III) coordination compounds were tested for their ability to inhibit TRAP activity and 
function. The gold(III) compound AubipyOMe strongly inhibited human recombinant TRAP 
activity (IC50 0.48 mM), and TRAP activity in mouse cell and human tissue extracts. Function-
ally, AubipyOMe inhibited mouse macrophage migration. In conclusion, this TRAP inhibitor 
could provide a useful tool to study the function of TRAP in lung.
A




Tartrate resistant acid phosphatase (TRAP) is a metalloenzyme and member of the purple 
acid phosphatases, containing a binuclear iron (Fe2+) center that facilitates the hydrolysis of 
phosphate esters and the generation of reactive oxygen species (ROS) 1-4. It is highly expressed 
in osteoclasts and alveolar macrophages and lower expression can be found in activated mac-
rophages and dendritic cells 1,2,4-9. TRAP exists in two isoforms: the 5a isoform is a monomer 
expressed in lysosomes, while the 5b isoform is a dimer derived from 5a by proteolytical 
cleavage and is the more active form 5,10-15. Alveolar macrophages have especially high expres-
sion of TRAP5a while osteoclasts express high levels of TRAP5b. The function of TRAP5b in 
bone has been studied in relation to bone remodeling, in which TRAP activity was found to 
mediate osteoclast migration. Osteoclasts are attached to bone matrix through an osteopon-




) bond. Migration of osteoclasts can only occur when this 
bond is disconnected by TRAP-dependent dephosphorylation of osteopontin 10,13,14,16. The role 
of TRAP5a in alveolar macrophages has not been clarified yet and specific, stable inhibitors 
to study its function lack.
Little is known about the regulation of TRAP in alveolar macrophages, in addition to its 
unknown function. One study investigated the expression of TRAP in lung tissue and another 
specifically measured TRAP expression in alveolar macrophages and both found higher 
expression in smokers 3,17-19. As TRAP may be involved in defending the lung against airborne 
dangers by its ability to generate oxygen radicals, we investigated whether its expression and/
or activity is altered in patients with fatal asthma or chronic obstructive pulmonary disease 
(COPD) 1,2,4,14. In both diseases we found either higher expression or higher activity of TRAP 
as compared to controls and we therefore continued to investigate its regulation by asthma 
and/or COPD-specific cytokines and mediators. 
Exploring the function of TRAP activity has been hampered due to lack of (specific) stable 
inhibitors. Hayman et al demonstrated inhibitory effects of gold chloride on TRAP activ-
ity 1-4,17-19. However, gold chloride is a reactive compound with a highly oxidative character 
and unspecific protein binding, whose activity may interfere with many different cellular 
pathways. In recent years, gold-based compounds of different families have been shown to 
possess ideal enzyme/protein inhibition properties, which allow them to be designed and 
exploited as chemical probes to study protein functions in biological systems and to possibly 
be developed as therapeutic agents 5-9,20,21. Thus, we decided to screen a series of gold coordi-
nation complexes with N-donor ligands, in which the gold(III) ions are known to be highly 
stabilized by the ancillary organic ligands. The presence of the ligand also allows designing 
the compounds to be selective for specific enzyme inhibition. Among the newly tested gold 





ure 1) was found to be the most potent inhibitor of TRAP activity. Therefore, we used this 
compound to investigate functional aspects of TRAP activity in macrophages, such as mac-
rophage migration.
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Our starting hypothesis was that TRAP activity in alveolar macrophages is involved in regu-
lation of their migration, similar to osteoclasts in bone. Osteopontin expression in lung has 
been shown on the luminal side of epithelial cells 11,15,22. As alveolar macrophages are present 




integrins, we hypothesized they may also 
need TRAP to migrate 10,12-14,23. We used this migration hypothesis to test the functionality of 




Gene expression data of TRAP was obtained from a large gene expression study comparing 
lung tissue from 311 patients with COPD and 270 non-COPD controls that were part of the 
Lung eQTL consortium. Details of this population can be found in supplemental table 1. Lung 
tissue samples were derived from patients with or without COPD undergoing lung tumor 
resection surgery or lung transplantation for severe COPD. In case of tumor resections, mac-
roscopically nontumorogenic lung tissue was taken far distant from the tumor and histology 
of all samples was checked for abnormalities using standard haematoxylin and eosin staining. 
Lung samples were obtained in accordance with local ethical guidelines. A detailed descrip-
tion of the whole genome mRNA profiling has been previously published by Brandsma et al. 
and Hao et al. 16-18,24. 
Asthma
Post mortem lung tissues from subjects with fatal asthma or subjects who died from non-
pulmonary causes (controls) were retrieved from the Department of Pathology of São Paulo 
University (São Paulo, Brazil). Patient characteristics can be found in supplemental table 
2. A detailed clinical and demographic description of this population has been previously 
published by Mauad et al. 25. For this study we investigated the presence of TRAP activity in 
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paraffin-embedded peripheral lung tissue samples of 10 asthma patients and 8 controls as 
described below.
Animal experiments
During the experiments, all animals were held under specific pathogen-free conditions in 
groups of 4-6 mice per cage in a temperature-controlled room with a 12h dark/light cycle 
and permanent access to food and water. The Institutional Animal Care and Use Committee 
approved these experiments according to strict governmental and international guidelines 
on animal experimentation (DEC2857, DEC5318, and DEC6416AA-001). 
Smoke-induced lung inflammation
To model COPD, we exposed five male A/JOlaHsd mice (Harlan, Horst The Netherlands, 8-10 
weeks old) nose-only to mainstream cigarette smoke for 9 months in an experimental set-up 
as described before by us 26. In short, mice were exposed daily to mainstream smoke from 
four 2R1 Reference Cigarettes (University of Kentucky, KY). This protocol was continued for 
5 days/week for 9 months. Six control mice were sham-exposed to room air under similar 
conditions, following the same duration of exposure as the smoke-exposed group. Mice were 
sacrificed after 9 months and lungs were collected, formalin-fixed and embedded in paraffin 
for histological analysis and TRAP-activity. 
Allergic lung inflammation
To model asthma, we exposed male and female BALB/c mice (Harlan, Horst The Netherlands, 
8-10 weeks old) intranasally to whole body house dust mite (HDM) extract (Dermatophagoi-
des pteronyssinus, Greer laboratories, Lenoir, USA) in 40 ml phosphate-buffered saline (PBS) 
according to a protocol we have described before 27. In short, mice (n=8) were exposed to 
HDM extract under isoflurane anesthesia: one time to a high dose of HDM (100 mg) in the 
first week and 5 times to a low dose (10 mg) in the second week. Control animals (n=8) were 
exposed to 40 ml PBS according to this same schedule. Mice were sacrificed on day 24, three 
days after the last HDM exposure and the right lung was inflated with 0.5 ml 50% Tissue-Tek® 
O.C.T.™ compound (Sakura, Finetek Europe B.V., Zoeterwoude, The Netherlands) in PBS and 
formalin-fixed for histological analyses and TRAP activity. Other parameters of allergic lung 
inflammation of these animals are described in detail by Draijer et al. 1,2,4,27.
Enzyme histochemistry for TRAP activity
Presence of active TRAP was assessed using a standard enzyme histochemical method. In 
short, deparaffinated lung sections (3mm) were rehydrated and incubated overnight in a 
buffer containing 0.1 M Tris at pH 7.4 supplemented with 30 mM calcium acetate, 23mM 
zinc acetate and 37mM zinc chloride, followed by pre-incubation in a 0.2 M acetate buffer at 
pH 5.0. TRAP-active cells were visualized by incubating sections for 0.5-4 hours at 37°C in a 
reaction solution containing 0.2 M acetate buffer with 0.5 mg/ml Naphtol AS-MX phosphate 
(Sigma-Aldrich, St. Louis, USA) and 1.1 mg/ml fast red TR salt (Sigma-Aldrich) at pH 5.0. After 
hematoxylin counterstaining, sections were imbedded in VectaMount Permanent mounting 
medium (Vector Laboratories, Burlingame, CA). The number of positive cells was counted 
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manually with the aid of ImageScope software (Leica Biosystems, Son, The Netherlands) in 
human and murine lung tissue sections, on average, a surface of 9 mm2 was measured of each 
section), and corrected for the surface area of the corresponding lung tissue (mm2).  
Cell culture of macrophages
Self-propagating murine alveolar-like macrophages (MPI macrophages, a kind gift from dr. G. 
Frejer, Plymouth University, Devon, UK) were cultured in RPMI 1640 medium (Gibco, Bleis-
wijk, The Netherlands) supplemented with 10% fetal bovine serum (FCS), gentamycin (10 
mg/ml), and GM-CSF (20 ng/ml) at 37°C under 5% CO
2
 and humidified conditions 1,2,4,28. MPI 
macrophages were plated at a density of 50,000 cells/well. The next day, cells were stimulated 
for 16h with a superoxide-generating system (0.2 mM Xanthine + 10mU/ml Xanthine oxidase 
(Sigma-Aldrich, St. Louis, USA)) to mimic oxidative stress, for 24h with the damage-asso-
ciated molecular pattern ATP (1, 10 or 100 mg/ml), for 24h with RANKL (200 ng/ml, kindly 
provided by dr. R.H. Cool, University of Groningen, The Netherlands), for 24h with IL-4 (10 
ng/ml), or for 24h with M-CSF (10 ng/ml). Cells were harvested for mRNA isolation purposes. 
RAW 264.7 macrophages (American Type Culture Collection) were cultured in Dulbecco’s 
modified Eagle’s medium (Invitrogen, The Netherlands) supplemented with 10% FCS, 2mM 





ditions. RAW macrophages were used in transwell and cell-tracking experiments, as further 
explained in “Inhibition of macrophage migration by AubipyOMe”.
Quantitative Real-Time PCR
For TRAP mRNA expression, RNA was isolated using the Maxwell® LEV simply RNA Cells/
Tissue kit (Promega, Madison, WI). Final mRNA concentrations after isolation were deter-
mined using a Nanodrop ND-100 spectrophotometer (Nanodrop Technologies, Wilmington, 
DE). Subsequently, cDNA was prepared using 10 ml mRNA (20 mg/ml) with 5x RT-buffer, 10 
mM dNTP’s, 5 units Rnasin, random primers and 40 units M-MLV Rev transcriptase. The 
Eppendorf Thermocycler (Eppendorf, Hamburg, Germany) was used for the amplification 
of the cDNA. Transcription levels of TRAP were measured in 20 ng cDNA per sample in a 
quantitative real-time PCR (SensiMix™ SYBR kit, Bioline, Taunton, MA) and the ABI7900HT 
sequence detection system (Applied Biosystems, Foster City, CA). Primers used for RT-PCR 
were obtained from Sigma-Aldrich (Zwijndrecht, The Netherlands): TRAP forward: 5’-GCT-
GTCCTGGCTCAAAAAGC-3’; TRAP reverse: 5’-CACACCGTTCTCGTCCTGAA-3’; GAPDH 
forward: 5’-ACAGTCCATGCCATCACTGC-3’; GAPDH reverse: 5’-GATCCACGACGGACA-
CATTG-3’. For each sample, the threshold cycles (Ct values) were calculated with the SDS 
2.3 software program (Applied Biosystems) and mRNA expression was normalized against 
GAPDH. The experiment was repeated at least four times.
Stimulation of precision cut lung slices
Lungs of male C57BL/6 mice (20-30 gr) of in total six mice were used to make precision-cut 
lung slices. Mice were sacrificed under isoflurane anaesthesia by exsanguination via the aorta 
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abdominalis. Lungs were filled with low-melting temperature agarose (1,5% in 0.9% NaCl) 
(Sigma-Aldrich) and transferred directly into ice-cold University of Wisconsin organ preser-
vation solution. Lung slices, diameter 5-mm and weight ±5 mg, were prepared with a Krum-
dieck tissue slicer (Alabama Research and Development, AL) using ice-cold Krebs-Hense-
leit Buffer [25 mM D-glucose (Merck, Darmstadt, Germany), 25 mM NaHCO3 (Merck), 10 





adjusted to pH 7.4] as described by us before for liver slices 5,29.
After slicing, murine lung slices were transferred to 12-well plates (Greiner bio-one, Alphen 
aan de Rijn, The Netherlands) with pre-warmed DMEM + Glutamax medium (1.3 ml) [4.5g/L 
D-glucose and pyruvate (Gibco) supplemented with non-essential amino acid mixture 
(1:100), 100 U/ml penicillin, 100 mg/ml streptomycin, 45 µg/ml gentamycin, and 10% FCS]. 




conditions and continuous shaking (90 
rpm), slices were transferred into fresh medium and incubated in triplicate with the following 
stimulants: vehicle, RANKL (200 ng/ml), ATP (10 µg/ml), or Xanthine (0.2 mM) + Xanthine 
oxidase (10 mU/ml). After 24 hours of incubation, the three slices of each condition were 
pooled and directly snap frozen in liquid nitrogen and stored at -80⁰C. For the TRAP activity 
analysis, 400 ml acetate buffer was added to each sample. Slices were then homogenized 
using small glass pearls and a Mini-Beadbeater-24 (45s) (Biospec products, Bartlesville, UK), 
centrifuged (10 min, 13.2 rpm, 4⁰C), and used immediately for the TRAP activity assay. 
TRAP activity assay on lysates of MPI macrophages and precision-cut lung slices
TRAP activity levels were determined with a TRAP activity assay. Lung slice homogenates 
or MPI-macrophage lysates were incubated at 37°C for an hour at a 1:1 ratio with an L-pa-
ra-Nitrophenylphosphate (PNPP) solution [100 mM PNPP, 200 mM sodium citrate, 200 mM 
sodium chloride, 80 mM sodium tartrate (L+), pH 4.5]. To stop the reaction, 1M NaOH was 
added and absorption at 410 nm, with 490 nm as a reference value, was measured using a 
spectrophotometer. Each sample was applied in duplicate and stimulus outcome was calcu-
lated relative to the nonstimulated control absorption level. Finally, the average TRAP-activity 
was calculated over six individual cell experiments or in lung tissue slices of six mice. 
Identification of TRAP inhibitors 
Initially, a small library of gold compounds was tested for TRAP inhibition using a TRAP activ-
ity assay (R&D, Minneapolis, USA) with recombinant human TRAP. The gold(III) compounds 
[Au(terpy)Cl]Cl
2










 (bipy = 2,2’-bipyr-




] (bipyOMe = 4,4’-dimethoxy-2,2’-bipyridine, 
AubipyOMe) 17-19,32 were synthesized according to literature procedures and their purity was 
confirmed by elemental analysis and showed to be >98 %. The anti-rheumatic gold(I) com-
pound sodium aurothiomalate (Authiomalate) was purchased from Sigma-Aldrich. NaAuCl
4
 
was used as a reference compound.
Inhibitor dilutions were prepared in acetate buffer from freshly prepared stock solutions (10 
mM in DMSO). Recombinant TRAP (1.25ng/ml) was incubated at 37°C for 30 minutes with 
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PNPP solution (1:1 ratio) and increasing concentrations of NaAuCl
4
 (range 0-40 μM) or gold 
compounds (range 0-5.1 μM). To stop the reaction, 1M NaOH was added and absorption at 
410 nm, with 490 nm as a reference value, was measured using a spectrophotometer.
Testing of inhibitors on cell and tissue lysates
Mouse alveolar macrophage lysates were obtained by resuspending 500.000 MPI macro-
phages in 1 ml acetate buffer. The cell suspension was sonicated, spun down (10 min, 13,200 
rpm), and the supernatant was collected for TRAP activity assays. Human lung lysates from 
COPD patients were used to test the inhibitor on human TRAP present in lung tissue. Lysates 
from in total 18 COPD patients were pooled (see supplemental table 3 for patients charac-
teristics). To obtain the tissue lysates, 10-20 mg frozen lung tissue was collected and 50 μl 
acetate buffer was added. Then, the tissue was homogenized manually using a small plunger. 
After spinning the samples down (13.200 rpm, 10 min, 4°C), all supernatants were pooled and 
stored at -80°C until use. 
AubipyOMe was tested in the range 0-40 μM with MPI lysates or pooled lung tissue lysates 
from COPD patients using a TRAP activity assay. MPI lysates were diluted 1:1 and COPD tissue 
lysates 1:20 with acetate buffer and incubated with increasing concentrations inhibitor, that 
were prepared from freshly made stock solutions (10 mM in DMSO) and diluted with acetate 
buffer. Lysates were incubated at 37°C for 30 min in the presence of PNPP solution (1:1 ratio). 
Adding 1M NaOH stopped the reaction and absorption was measured at 410 nm with 490 nm 
as a reference value. 
The inhibitory effects of gold compounds were calculated as the ratio of absorbance between 
the treated and untreated wells. The IC50 value was calculated as the concentration of inhib-
itor causing a 50% reduction in TRAP activity. The average IC50 of three independent exper-
iments was calculated.
MTT assay
The effect of AubipyOMe and NaAuCl
4
 on cell growth was assessed with a classical MTT assay. 
RAW macrophages were seeded in 96-well plates (Greiner bio-one) at a concentration of 
10,000 cells/well and grown for 24h in complete medium. Compound dilutions were pre-
pared in complete medium from a freshly prepared stock solution (10 mM in DMSO) and 
added to the wells (200 μl) to obtain a final concentration (0 to 100 μM). Cells were incubated 
for 72h after which 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was 
added to the cells at a final concentration of 0.50 mg/ml and incubated for 3h. After 3h, the 
MTT-solution was removed and the violet formazan crystals dissolved in DMSO. The opti-
cal density of each well was quantified in quadruplicate at 540 nm, using a multi-well plate 
reader, and the percentage of surviving cells was calculated from the ratio of absorbance 
between treated and untreated cells. The IC50 value over four individual experiments was cal-
culated as the actual concentration of inhibitor reducing the proliferation of the cells by 50%. 
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Inhibition of macrophage migration by AubipyOMe
Transwell experiment 
Migration of RAW macrophages was assessed using a transwell-culturing system with inserts 
(Sigma-Aldrich, St. Louis, USA) coated with osteopontin (R&D, Minneapolis, UK). Bovine 
collagen-coated inserts (Advanced Biometrix, Carlsbad, USA) were used as a matrix control. 
RAW macrophages, pre-stimulated with 200 ng/ml RANKL for 72h to induce TRAP activity, 
were seeded on 8 mm pore inserts coated with osteopontin (10 mg/ml, 250,000 cells/well) or 
collagen (10 μg/ml, 250,000 cells/well). Cells were cultured for 16h in the presence or absence 
of AubipyOMe (128 nM) in quadruplicate. The next day, total cell numbers in the lower com-
partment, including dead cells, were counted. The number of cells migrated to the lower well 
was calculated relative to cells not stimulated with RANKL and an average of six individual 
experiments was calculated. 
Confocal imaging of macrophage migration
Briefly, RAW macrophages were plated on osteopontin-coated (10 mg/ml, R&D) Lab-tek 
chamber slides (Nunc, Hatfield, USA) at a density of 7500 cells/well. Half of the wells were 
stimulated with RANKL (200 ng/ml) for 48 hours to induce TRAP activity, followed by CFSE 
labeling (5-(and 6)-Carboxyfluorescein diacetate succinimidyl ester, CFSE, Invitrogen, Life 
Technologies Europe BV, Bleiswijk, The Netherlands) to visualize cells for live cell imaging 
using a confocal microscope (Solamere Nipkow Confocal Live Cell Imaging system, Solamere 
Technology Group, Salt lake city, USA). A solution of 4mM CFSE in PBS (400 ml) was added 
to the cells for 20 min. After washing the cells with medium, new medium was applied (200 
ml) with or without AubipyOMe (128 nM). Cell movement was tracked overnight in the pres-
ence of 1% zymosan solution (Sigma-Aldrich, St. Louise, USA) to stimulate cell movement. 




. Pictures were taken every 
10 min and were transformed into movies each representing one well with Image J 1,2,4,33 and 
Imaris x64 (Bitplane, Zurich, Switzerland) software. 
Statistical analysis
All data were nonparametrically distributed. Statistical differences between two groups were 
calculated using a Mann-Whitney U test. When comparing multiple conditions, a nonpara-
metric Kruskal-Wallis with a Dunn’s multiple comparisons test was performed. When study-
ing correlations, a Spearman coefficient was calculated to test for significance. P<0.05 was 
considered significant.
Results 
TRAP expression and TRAP activity in COPD and (fatal) asthma 
To assess whether TRAP mRNA expression is changed in COPD versus control lung tissue we 
did a single gene look-up for TRAP in a genome wide gene expression dataset comparing 311 
COPD patients and 270 non-COPD controls 16,34. Amongst the upregulated genes was TRAP, 
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which was significantly higher in COPD patients compared to control patients (p<0.0008, 
figure 2A). To investigate the effect of current smoking on TRAP expression, we additionally 
compared control individuals currently smoking with individuals that had stopped smoking 
for at least 5 years in the same dataset. This comparison showed higher expression of TRAP 
in the individuals that are currently smoking versus the ex-smokers (figure 2B). A similar 
analysis among the COPD patients showed no differences between current and ex-smokers. 
In addition, we examined whether TRAP mRNA expression correlated with lung function in 
COPD patients (as defined by FEV
1
) and found a negative correlation, meaning higher TRAP 
expression was linked with lower FEV1 values (p<0.04, figure 2C). This significant correlation 
Figure 2. High TRAP expression is associated with COPD. (A) TRAP mRNA expression was 
significantly higher in patients with COPD (n=311) as compared to their respective controls 
(n=270). (B) TRAP mRNA expression was significantly higher in control individuals that were 
current smokers (n=73) in contrast to control exsmokers after at least 5 years of smoking cessa-
tion (n=106). (C) TRAP mRNA expression correlated negatively with lung function (FEV
1
). (D) 
TRAP mRNA expression is only significantly higher in patients with severe COPD (GOLD stage 
IV) as compared to controls. Differences were tested using a Mann-Whitney U test, * P<0.05, ** 
P<0.01, *** P<0.001. The correlation between TRAP mRNA expression and FEV
1
 was calculated 
using a Spearman correlation coefficient, * P<0.05.
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is mainly caused by the high expression of TRAP in lung tissue of patients with severe COPD: 
patients with the most severe disease, i.e. highest GOLD stage and therefore lowest FEV1 
value, had significantly higher expression of TRAP in lung tissue as compared to non-COPD 
controls, while the patients with less severe COPD had similar TRAP expression as compared 
to controls (figure 2D).
Figure 3. High TRAP activity is associated with fatal asthma. (A) Parenchymal lung tissue of 
patients with fatal asthma (n=10) contained higher numbers of TRAP-positive macrophages as 
compared to controls dying of nonpulmonary causes (n=8). (B) Representative pictures of lung 
tissue sections of a control individual stained for TRAP activity. (C) Representative pictures of 
lung tissue sections of a fatal asthma patient stained for TRAP activity. Cells positive for TRAP 
(purple) are alveolar macrophages as indicated by the arrows. Differences were tested using a 
Mann-Whitney U test, * P<0.05.
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To investigate the activity levels of TRAP in fatal asthma, we compared lung sections of 
patients who had died during an asthma attack with lung sections from controls who had 
died of nonpulmonary causes. Staining for TRAP activity showed that the number of cells 
positive for TRAP activity was higher in lung tissue from patients with fatal asthma as com-
pared to control subjects (figure 3A-C). Only alveolar macrophages were found to be TRAP 
activity-positive (figure 3B, indicated by the arrows), though not all alveolar macrophages 
seemed positive for TRAP activity.
Figure 4. High TRAP activity is associated with exposure to smoke and house dust mite. 
(A) Parenchymal lung tissue of mice that were exposed to cigarette smoke for 9 months (n=5) 
contained a higher number of TRAP+ alveolar macrophages than mice exposed to room air 
(n=6) as determined by the number of positive cells/mm2. (B-C) Representative pictures of lung 
tissue sections of a control mouse and a smoke-exposed mouse stained for TRAP activity. Alveo-
lar macrophages stain positive for TRAP (purple) as indicated by the arrows. (D) Mice exposed 
to house dust mite (n=8) showed higher numbers of TRAP+ alveolar macrophages in paren-
chymal lung tissue compared with control mice (n=8) as determined by the number of positive 
cells/mm2. (D-F) Representative pictures of lung tissue sections of a control mouse and a house 
dust mite-exposed mouse stained for TRAP activity. Alveolar macrophages stain positive for 
TRAP (purple) as indicated by the arrows. Differences were tested using a Mann-Whitney U 
test, ** P<0.01, *** P<0.001.
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In lungs of mice that were exposed to cigarette smoke for 9 months we found that the number 
of TRAP-active cells was significantly higher as compared to air-exposed mice (figure 4A). 
Sections of the lung show that alveolar macrophages stain positive for TRAP activity (figure 
4B-C, indicated by the arrows). In a model of house dust mite (HDM)–induced asthma, we 
also found significantly higher numbers of TRAP-positive cells in the parenchyma of mice 
exposed to HDM as compared to vehicle-exposed control mice (figure 4D). Again, alveolar 
macrophages were the only cells that stained positive for TRAP activity (figure 4E-F, indicated 
by the arrows).
TRAP expression is upregulated by RANKL and oxidative stress
In order to study what causes the higher activity and/or expression of TRAP in alveolar mac-
rophages, we exposed MPI alveolar-like macrophages and murine precision-cut lung slices 
to various stimuli related to COPD and asthma, namely IL-4, M-CSF and RANKL, the dam-
age-associated molecular pattern ATP, and oxidative stress mimicked by the xanthine/xan-
thine oxidase (X/XO) system. TRAP mRNA expression in MPI alveolar-like macrophages was 
significantly higher after stimulation with RANKL and the X/XO system (figure 5A). TRAP 
expression was significantly lower after M-CSF incubation. There was no significant effect 
observed of ATP or IL-4 stimulation. To subsequently study TRAP activity we used lung slices 
incubated with RANKL, ATP and the X/XO system and measured TRAP activity in the slices. 
RANKL treatment resulted in significantly higher TRAP activity, but ATP and X/XO treatment 
did not (figure 5B). 
The gold compound AubipyOMe inhibits TRAP activity
To be able to study TRAP function, we evaluated a group of gold-containing compounds as 
possible TRAP activity inhibitors. Thus, a series of gold coordination compounds (including 
mono- and di-nuclear Au(III) compounds with N-donor ligands, as well as the anti-rheu-
matic agent sodium aurothiomalate (Myochrysine®, see supplemental figure 1 for the struc-
tures of the compounds tested) were tested for their ability to inhibit recombinant human 
TRAP activity. 
The initial screening revealed that the compound AubipyOMe possessed the best TRAP 
activity inhibitory capacities compared to the previously described TRAP activity inhibitor 
NaAuCl
4
 3,35. Both AubipyOMe and NaAuCl
4 
inhibited the activity of recombinant TRAP in a 
dose-dependent manner (figure 6A) with IC50 values in the nM range (see table 1 for a com-
plete overview of the IC50 values). We therefore continued testing AubipyOMe and NaAuCl
4
, 
the latter used as 
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Recombinant TRAP MPI macrophages 
cell lysates
COPD patients cell lysates
NaAuCl4 0.280 ±0.095 0.470 ±0.477 4.12 ±2.65
AubipyOMe 0.476 ±0.666 2.951 ±2.095 13.98 ±5.61
Authiomalate No inhibition - -
Auterpy* 1.643 ±1.437 - -
Auoxo1 No inhibition - -
*: Auterpy was found to be toxic to macrophages.
reference compound, in more relevant biological settings. Indeed, TRAP activity in cell 
lysates of MPI macrophages was also significantly inhibited in the presence of AubipyOMe 
or NaAuCl
4
 with IC50 values of 2.95±2.1 mM and 0.47±0.48 mM respectively (figure 6B). Impor-
tantly, the inhibitory effects of AubipyOMe and NaAuCl
4
 were also tested on TRAP activity in 
pooled lung lysates from COPD patients. AubipyOMe significantly inhibited TRAP activity in 
these lysates with an IC50 value of 14.0±5.6 mM, while NaAuCl
4
 inhibited the activity with an 
IC50 value of 4.1± 2.7 mM (figure 6C). In addition, AubipyOMe only had cytotoxic effects on 
RAW macrophages in very high concentrations (IC50 ca. 30 mM, figure 6D) and AuCl
4
 did not 
display significant toxicity (IC50>200 mM).
Figure 5. RANKL and oxidative stress are inducers of TRAP. (A) TRAP mRNA expression 
in MPI macrophages was higher after stimulation with xanthine/xanthine oxidase and after 
RANKL (200ng/ml) stimulation. M-CSF (10ng/ml) significantly downregulated TRAP mRNA 
expression. ATP (10mg/ml) and IL-4 (10ng/ml) had no effect. (B) TRAP activity was higher in 
precision-cut lung slices incubated with RANKL (200ng/ml) and no effect on TRAP activity was 
seen following stimulation with ATP (10mg/ml) or oxidative stress (10mU/ml). Stimulus out-
come was calculated relative to the vehicle control. Results shown represent at least four inde-
pendent experiments and differences were tested by a two-way Kruskal-Wallis and a Dunn’s 
post test, *P<0.05.
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Macrophage migration depends on TRAP activity and is inhibited by AubipyOMe
Osteoclast migration is suggested to be TRAP-dependent through the ability of TRAP to 
dephosphorylate osteopontin 14,36. To investigate if this is also the case for macrophages we 
used RAW 264.7 macrophages because we could modulate TRAP activity from low to high by 
pretreating with RANKL in these cells, which we could not do in the same extent with MPI 
macrophages. We induced TRAP activity in macrophages with RANKL and incubated cells 
with or without AubipyOMe to investigate effects of TRAP activity and the inhibition of TRAP 
Figure 6. AubipyOMe is a potent TRAP inhibitor. (A) TRAP activity of commercially pur-
chased recombinant human TRAP was inhibited by NaAuCl
4
 (IC50: 0.28±0.09 mM) and by 
AubipyOMe (IC50: 0.48±0.67 mM). (B) TRAP activity in lysates of murine MPI macrophages 
was inhibited by NaAuCl
4
 (IC50: 0.47±0.48 mM) and by AubipyOMe (IC50: 3.0±2.1 mM). (C) 
TRAP activity in lysates from COPD lung tissue was inhibited by NaAuCl
4
 (IC50: 4.1±2.7 mM) 
and by AubipyOMe (IC50: 14.0±5.6 mM). The inhibitory effect was calculated as the ratio of 
absorbance between treated and untreated cells. The IC50 value was calculated as the con-
centration of inhibitor causing a 50% reduction in TRAP activity. Data represent at least three 
independent experiments. (D) MTT assay performed on RAW 264.7 macrophages resulted in 
an IC50 value of 29.3±4.6 mM for AubipyOMe. NaAuCl4 inhibited cell growth with an IC50 
value of >200 mM. The percentage of cell viability was calculated from the ratio of absorbance 
between treated and untreated cells. The IC50 value was calculated as the concentration inhib-
itor reducing the proliferation of the cells by 50%. Data is presented as a mean ±SEM of four 
independent experiments. 
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activity on macrophage cell migration in a transwell setup. Cells prestimulated with RANKL 
migrated significantly more through an osteopontin-coated membrane into the lower com-
partment as compared to unstimulated cells (figure 7A). RANKL stimulation in combination 
with the inhibitor AubipyOMe led to significantly less migration of macrophages as compared 
to just RANKL stimulation. Incubation with the inhibitor alone did not affect macrophage 
migration. This effect was osteopontin-specific because RANKL stimulation did not lead to 
enhanced migration through a collagen-coated membrane and this was also not influenced 
by the inhibition of TRAP activity by AubipyOMe (figure 7B). 
Figure 7. TRAP is involved in macrophage migration. (A) In a transwell set-up, RAW 264.7 
macrophages were allowed to migrate over an osteopontin-coated membrane with or with-
out RANKL stimulation (200ng/ml). RANKL-stimulated macrophages migrated significantly 
more through an osteopontin-coated membrane as compared to vehicle-stimulated macro-
phages. (B) RAW 264.7 macrophages were allowed to migrate through a collagen-coated mem-
brane with or without RANKL stimulation (200ng/ml). No differences were observed between 
RANKL stimulated and unstimulated conditions. The number of cells that had migrated from 
the insert to the bottom well was calculated relative to the number of unstimulated cells that 
had migrated. Each experiment was performed in quadruplicate and performed 6 times. (C) 
Live cell tracking of macrophages in an osteopontin-coated well revealed that macrophage 
migratory behavior was higher in the presence of RANKL (200ng/ml) as compared to the vehi-
cle-treated control and AubipyOMe inhibited this migration (movies are provided in the online 
supplemental data, Movies 1-4). Differences were tested with a Kruskal-Wallis test and a Dunn’s 
post test, *P<0.05.
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Furthermore, we investigated whether RANKL stimulation of RAW macrophages led to 
increased macrophage migration using a live cell imaging. Cells that were plated on wells 
coated with osteopontin showed more migratory behavior following RANKL stimulation 
(figure 7C, movie 1 versus 2 in supplemental data) than unstimulated cells. This increased 
migratory behavior was not observed in the presence of AubipyOMe (figure 7C, movies 3 and 
4, supplemental data). 
Discussion 
We observed high TRAP expression in the lungs of COPD patients and high TRAP activity in 
the lungs of fatal asthma patients and mouse models of COPD and asthma. This increase may 
be triggered by RANKL and/or oxidative stress, though the functional consequences of this 
higher expression and activity remain to be determined. To aid the elucidation of the role of 
TRAP in the lungs, we developed a new type of TRAP-inhibitor: AubipyOMe. This gold(III) 
bearing compound is a potent inhibitor of the phosphatase function of TRAP and using this 
inhibitor we first studied whether AubipyOMe was able to inhibit macrophage migration, as 
this is one of the known functions of TRAP in osteoclasts and this may also apply to (alveo-
lar) macrophages. We indeed showed that higher TRAP activity may be related to enhanced 
migration of (alveolar) macrophages and that our inhibitor was able to limit migration. 
To the best of our knowledge, TRAP expression levels have never been studied before in rela-
tion to COPD. Only two studies looked at the effect of smoking, the most important risk fac-
tor of COPD, on TRAP mRNA and/or protein expression: one reported higher TRAP mRNA 
expression in the lungs of smokers and the other showed higher TRAP protein levels in alve-
olar macrophages obtained from smokers 17-19,37,38. Our results confirm that current smoking 
results in higher TRAP mRNA expression and we additionally show that TRAP activity is 
higher in the lungs of mice exposed to cigarette smoke. Moreover, TRAP mRNA expression is 
also higher in lung tissue of COPD patients compared with controls, independent of smoking 
status. TRAP mRNA expression is higher with the highest disease severity, therefore, a dis-
ease-specific factor may be causing the increase in TRAP expression on top of smoking-re-
lated induction of TRAP. 
TRAP has not been studied in the context of asthma as well. This chronic lung disease has a 
different pathogenesis from COPD but was also characterized by higher numbers of TRAP-ac-
tive macrophages in lung tissue in both fatal asthma and a murine model of asthma as com-
pared to controls. This higher number of TRAP-active macrophages most likely results from 
an increase in TRAP activity, as all alveolar macrophages express TRAP protein, but not all 
of it is found to be active (data not shown). Furthermore, Draijer et al. showed that the actual 
number of alveolar macrophages remained unchanged after induction of asthma 27, confirm-
ing this conclusion. Hence, we investigated some overlapping cytokines and conditions of 
both obstructive lung diseases to identify the cause of the high TRAP expression and TRAP 
activity in these lung diseases. 
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When considering the regulation of TRAP in lung diseases, in vitro experiments showed 
that the most likely candidate to induce TRAP expression/activity is RANKL. RANKL is a 
well-known inducer of TRAP expression in osteoclasts (multinuclear bone macrophages) 
and was included as a positive control. However, higher levels of RANKL have also shown 
to be present in patients with COPD, especially those suffering from osteoporosis, a known 
comorbidity of emphysematous COPD 20,21,39. Therefore, the high levels of circulating RANKL 
may explain the high TRAP expression and activity in lung tissue of COPD patients. The fact 
that especially GOLD stage IV patients, transplanted for severe COPD, have the highest mRNA 
expression of TRAP is in line with this observation. The high RANKL levels may explain the 
high TRAP expression and activity in COPD; it does not explain the high TRAP activity found 
with fatal asthma patients. To our knowledge, no reports have been published about the levels 
of RANKL in (fatal) asthma patients, therefore it is unclear whether and how RANKL could 
play a role in (fatal) asthma. 
Our results furthermore showed that TRAP mRNA expression is higher in macrophages cul-
tured under high-oxidative-stress conditions. Indeed, oxidative stress is a known inducer of 
osteoclast formation accompanied by increased TRAP5b expression in these cells 22,31. Patients 
with COPD have been shown to have high levels of oxidative and nitrosative stress in their 
lungs 34,40 and in asthma basal oxidative stress levels are elevated as a result of chronic inflam-
mation 35,41,42. Local anti-oxidants apparently possess insufficient capacity to counteract this 
oxidative stress 36,41,43, which in turn may affect macrophage TRAP mRNA expression 1,37,38,43,44. 
Interestingly, the higher TRAP expression following oxidative stress in macrophages in vitro 
did not result in higher TRAP activity in lung slices that were cultured under similar condi-
tions. The reason for this disconnect is unclear but may relate to the slicing and subsequent 
incubation of lung tissue, which may have exhausted reducing agents like superoxide dis-
mutase in the tissue that are necessary for optimal TRAP activity 4,41,42. 
TRAP itself may also contribute to oxidative stress levels in the lung through its oxygen radical 
producing potential. Alveolar macrophages are an important first-line defense against patho-
gens and their TRAP expression was shown to contribute to ROS formation and bacterial 
killing 41,43,45,46. In addition, evidence already supports a role for TRAP in immune-regulatory 
processes in the lung 1,43,44,47. The monomeric, intracellular TRAP5a isoform can generate cel-
lular oxidative stress through oxidation of one of the iron atoms of TRAP 43,48,49. As both COPD 
and asthma are characterized by high oxidative stress conditions, high TRAP expression/
activity may even contribute to these levels. 
To further aid the study of the function of (elevated) TRAP activity in alveolar macrophages, 
we developed a new potent TRAP inhibitor, namely the gold(III) compound AubipyOMe, 
that effectively inhibits the activity of human and murine TRAP. In addition to its contribu-
tion to intracellular ROS production, TRAP can act as a phosphatase and dephosphorylate 
osteopontin 41,43,50,51. Our inhibitor has been tested as a phosphatase inhibitor only, and we 
therefore investigated a possible function of the phosphatase activity. For osteoclasts it has 
been shown that the extracellular TRAP5b isoform activity contributes to osteoclast migration 
by dephosphorylation of osteopontin thereby reducing (α
v3
-integrin-mediated) cell adhesion 
of osteoclasts 14,52-58. We now show that TRAP activity in macrophages has a similar function, 
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because upregulation of TRAP by RANKL stimulation resulted in more macrophage migra-
tion. In addition, subsequent inhibition of the phosphatase function of TRAP by AubipyOMe 
inhibited macrophage migration. 
Functional consequences of enhanced macrophage migration in lung tissue in diseases like 
COPD and asthma remain to be investigated. Work of the group of Väänänen et al. showed 
that TRAP is involved in matrix degrading processes by assisting in trafficking of collagens 
in vesicles through the cell and that TRAP colocalized with phagocytosed material within 
alveolar macrophages 4,41,59-62. Therefore, alveolar macrophage TRAP may be involved in the 
tissue remodeling processes that play a role in both asthma and COPD. Another possible role 
for TRAP in COPD and asthma could be the regulation of interferon alpha (IFNα) production. 
Both COPD and asthma are characterized by exacerbations, often induced by viral infections 
16-18,45,46. IFNα is important in defenses against viruses and Briggs et al. recently showed that 
TRAP inhibits IFNα production by regulating intracellular levels of phosphorylated osteo-
pontin in dendritic cells 24,47. Expression of nonfunctional TRAP led to higher levels of IFN 
and therefore high expression of TRAP (like in COPD and asthma) may result in a lower 
IFNα production. Indeed, lower levels of IFN have been detected in patients with asthma 
and COPD 25,48,49. The gold-based TRAP inhibitor AubipyOMe could be used to investigate the 
role of TRAP in IFNα production by alveolar macrophages. An unexpected outcome was the 
clear downregulation of TRAP expression in alveolar-like macrophages after M-CSF stimula-
tion. In the bone field, many publications have shown that M-CSF is necessary for osteoclast 
formation as determined by the formation of TRAP-expressing/TRAP-active multinucleated 
cells. This discrepancy in M-CSF responsiveness may be caused by the fact that we used alve-
olar-like macrophages, which are derived from fetal monocytes/yolk sac macrophages and 
self-maintain in lung tissue during life, while osteoclasts are derived from hematopoietic stem 
cells and replenished from bone marrow 27,52,54,56,57. Since alveolar macrophages are particu-
larly dependent on GM-CSF for their development, this could explain the discrepancy in the 
response to M-CSF 59,61,62.
There are still some unknown aspects regarding the inhibitor we developed. For example, its 
selectivity should be studied in more detail to elucidate whether AubipyOMe also inhibits 
other phosphatases or enzymes. In addition, it would be of interest to determine the affinity 
of AubipyOMe towards the two TRAP isoforms, namely the TRAP5a monomer and the more 
active TRAP5b dimer, as their functions differ 41. Therefore, structural modifications to the 
inhibitor could be considered to improve its selectivity and affinity. Moreover, we have shown 
AubipyOMe inhibits the phosphatase function of TRAP, but it is unknown whether this inhib-
itor can affect ROS production. 
In conclusion, TRAP expression and activity are high in COPD and fatal asthma and in rele-
vant mouse models. One of the roles of TRAP may be to facilitate macrophage migration and 
ROS production, but the consequences of such effects on the pathogenesis of COPD and 
(fatal) asthma are still unclear. The development of our potent gold-based TRAP inhibitor 
now allows more detailed studies into the function of TRAP in the lung and diseases of the 
lung characterized by higher TRAP activity such as asthma and COPD.
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Supplemental table 1. Patient characteristic of patients with and without fatal asthma 
(median + range is displayed).
Control (n=8) Fatal asthma (n=10)
Sex, male/female 5/3 5/5












Supplemental table 2. Patient characteristic of COPD patients from whom lung tissue was 
used for the preparation of lung tissue lysates (median + range is displayed).
COPD (n=18)
Sex, male/female 12/6
Age, years 66 (35-80)
Smoking status 18 ex-smoker
FEV1 % pred. 62 (36-77)
GOLD stage GOLD II = 15
GOLD III = 3
Supplemental able 3. Patient characteristics of control and COPD patients used to assess 
TRAP mRNA expression (median + range is displayed).
Control (n=270) COPD (n=311)
Sex, male/female 145/125 182/129
Age, years 61 (37-80) 63 (33-84)




FEV1 % pred. 98% (80-136) 57 (11-83)
FEV1/FVC 76 (70-91) 53 (16-70)
GOLD stage - GOLD I = 1, GOLD II = 216
GOLD III = 27, GOLD IV = 56 Undetermined = 11
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Supplemental figure 1. Chemical structures of the gold-containing compounds tested for their 
potential TRAP inhibitory capacities.
Movies 1-4
Live cell tracking of macrophages on an osteopontin-coated well revealed that macro-
phage migration was higher in the presence of RANKL (200ng/ml) as compared to the vehi-
cle-treated control and AubipyOMe inhibited this mobility. Live cell tracking of macrophages 
was conducted in the presence of a vehicle control (Movie 1), RANKL (200ng/ml) (Movie 2), 
the inhibitor AubipyOMe (320ng/ml) (Movie 3) and RANKL (200ng/ml) in combination with 
the inhibitor AubipyOMe (320ng/ml) (Movie 4). 
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